BP
GSK icon

Ballentine Partners’s GSK GSK Stock Holding History

Ballentine Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
22,415
+2,325
+12% +$123K 0.01% 334
2026
Q1 		$1.11M Buy
20,090
+1,945
+11% +$105K 0.02% 330
2025
Q4 		$890K Sell
18,145
-1,341
-7% -$62.5K 0.01% 351
2025
Q3 		$841K Sell
19,486
-255
-1% -$9.96K 0.01% 365
2025
Q2 		$758K Sell
19,741
-465
-2% -$17.8K 0.01% 371
2025
Q1 		$783K Buy
20,206
+3,056
+18% +$112K 0.01% 339
2024
Q4 		$580K Buy
17,150
+4,959
+41% +$179K 0.01% 396
2024
Q3 		$498K Buy
12,191
+125
+1% +$5.11K 0.01% 421
2024
Q2 		$465K Sell
12,066
-3,015
-20% -$127K 0.01% 419
2024
Q1 		$647K Sell
15,081
-3,680
-20% -$152K 0.01% 339
2023
Q4 		$695K Sell
18,761
-2,639
-12% -$94.7K 0.01% 294
2023
Q3 		$776K Buy
21,400
+1,466
+7% +$52K 0.02% 232
2023
Q2 		$710K Buy
19,934
+5,072
+34% +$182K 0.02% 245
2023
Q1 		$529K Sell
14,862
-73
-0.5% -$2.55K 0.01% 293
2022
Q4 		$525K Buy
14,935
+4,324
+41% +$144K 0.02% 273
2022
Q3 		$313K Sell
10,611
-6,206
-37% -$235K 0.01% 334
2022
Q2 		$915K Sell
16,817
-4,311
-20% -$238K 0.03% 161
2022
Q1 		$1.15M Buy
21,128
+4,278
+25% +$232K 0.04% 155
2021
Q4 		$929K Buy
16,850
+2,084
+14% +$108K 0.03% 185
2021
Q3 		$706K Buy
14,766
+2,723
+23% +$137K 0.02% 192
2021
Q2 		$600K Buy
12,043
+267
+2% +$12.8K 0.02% 212
2021
Q1 		$525K Sell
11,776
-2,108
-15% -$95.7K 0.02% 217
2020
Q4 		$639K Buy
13,884
+234
+2% +$10.7K 0.03% 186
2020
Q3 		$642K Sell
13,650
-356
-3% -$17.8K 0.03% 183
2020
Q2 		$714K Buy
14,006
+1,253
+10% +$64.3K 0.03% 172
2020
Q1 		$604K Sell
12,753
-2,255
-15% -$120K 0.04% 170
2019
Q4 		$881K Buy
15,008
+621
+4% +$34.5K 0.04% 166
2019
Q3 		$767K Buy
14,387
+70
+0.5% +$3.6K 0.04% 172
2019
Q2 		$716K Sell
14,317
-152
-1% -$7.63K 0.03% 180
2019
Q1 		$756K Buy
14,469
+1,080
+8% +$54K 0.04% 157
2018
Q4 		$639K Sell
13,389
-908
-6% -$44.7K 0.04% 167
2018
Q3 		$718K Buy
14,297
+211
+1% +$10.7K 0.04% 162
2018
Q2 		$710K Buy
14,086
+4,270
+44% +$215K 0.04% 150
2018
Q1 		$479K Buy
9,816
+1,121
+13% +$52.2K 0.03% 184
2017
Q4 		$386K Buy
8,695
+565
+7% +$26.1K 0.02% 225
2017
Q3 		$413K Sell
8,130
-540
-6% -$27.4K 0.02% 221
2017
Q2 		$451K Buy
8,670
+439
+5% +$23.4K 0.03% 213
2017
Q1 		$434K Sell
8,231
-35
-0.4% -$1.78K 0.03% 135
2016
Q4 		$398K Buy
8,266
+464
+6% +$22.9K 0.03% 132
2016
Q3 		$421K Hold
7,802
– – 0.03% 112
2016
Q2 		$423K Sell
7,802
-820
-10% -$43.2K 0.04% 123
2016
Q1 		$437K Buy
8,622
+1,305
+18% +$65K 0.04% 120
2015
Q4 		$369K Sell
7,317
-917
-11% -$46.7K 0.04% 120
2015
Q3 		$395K Buy
8,234
+1,164
+16% +$60.6K 0.04% 107
2015
Q2 		$368K Sell
7,070
-58
-0.8% -$3.27K 0.04% 116
2015
Q1 		$411K Sell
7,128
-29
-0.4% -$1.66K 0.04% 104
2014
Q4 		$383K Buy
+7,157
New +$400K 0.04% 111

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
BB
Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return
KIC
Keating Investment Counselors Delray Beach, Florida $364M AUM 22.11% 1-Year Est. Return
GHAM
Gilman Hill Asset Management New Canaan, Connecticut $731M AUM 19.41% 1-Year Est. Return
AWAG
ARS Wealth Advisors Group St. Petersburg, Florida $1.28B AUM 24.51% 1-Year Est. Return
HAI
Hennessy Advisors Inc Novato, California $3.13B AUM 77.26% 1-Year Est. Return

Ballentine Partners's GSK Position: Q2 2026 in Review

Ballentine Partners increased its GSK (GSK) stake by 12% in Q2 2026, buying an estimated $123K and bringing the position to 22,415 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #334.

Ballentine Partners first reported a position in GSK in Q4 2014 and has held it in 47 quarters since. 161 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Ballentine Partners held 22,415 shares of GSK worth $1.17M as of Q2 2026.
  • Ballentine Partners bought 2,325 GSK shares in Q2 2026, an estimated $123K.
  • GSK made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #334 holding.
  • Ballentine Partners first reported a position in GSK in Q4 2014 and has held it in 47 quarters since.
  • 161 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.